IMAGE-HF Project I-C: Computed Tomographic Coronary Angiography for Heart Failure Patients (CTA-HF)

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by Ottawa Heart Institute Research Corporation
Canadian Institutes of Health Research (CIHR)
The Finnish Funding Agency for Technology and Innovation (TEKES)
Information provided by (Responsible Party):
Rob Beanlands, University of Ottawa Heart Institute Identifier:
First received: January 20, 2011
Last updated: August 29, 2014
Last verified: August 2014

Background: The prevalence of heart failure (HF) is rapidly rising in industrialized and developing countries. Though invasive coronary angiography (ICA) remains the gold standard for anatomical assessment of coronary arteries and luminal stenoses in these patients, alternatives have been sought. Computed tomographic coronary angiography (CTA) has emerged as an accurate non-invasive diagnostic tool for CAD and has been demonstrated to have prognostic value. Whether or not CTA can be used in patients with HF for diagnosis and to guide patient investigations and management is unknown. Acknowledging the aging population in industrialized counties, the increasing burden of healthcare and growing prevalence of HF, there is a need to identify non-invasive diagnostic tests that are cost-effective, readily available, safe and of sufficient accuracy to risk stratify patients and guide investigations and management.

Methods: The proposed study aims to provide insight into the efficacy of CTA for clinical use in distinguishing heart failure etiologies and guiding subsequent patient management. This proposed multicentre randomized controlled trial will enrol 250 HF patients requiring coronary anatomical definition. Enrolled patients will be randomized to either CTA or ICA diagnostic arms. Outcomes will be collected to determine the health economics associated with each diagnostic strategy. Analysis of composite clinical events and major adverse cardiac events will be performed to determine the impact of these strategies upon patient outcomes. Accuracy of CTA in detection of coronary anatomy and obstruction will be assessed in patients undergoing ICA. It is expected that CTA will be a more cost-effective strategy for diagnosis; yielding similar outcomes with fewer procedural risks and improved resource utilization.

Condition Intervention
Heart Failure
Other: Standard Imaging
Other: Advanced Imaging

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: Computed Tomographic Coronary Angiography for Heart Failure Patients (CTA -HF) Project I-C of Imaging Modalities to Assist With Guiding Therapy and the Evaluation of Patients With Heart Failure (IMAGE-HF)

Resource links provided by NLM:

Further study details as provided by Ottawa Heart Institute Research Corporation:

Primary Outcome Measures:
  • Resource Utilization and cost [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Cost: the incremental cost of the diagnostic strategy using CTA will be the primary endpoint and will be estimated through regression methods.

Secondary Outcome Measures:
  • Clinical Endpoints [ Time Frame: 3 months, 1, 2 and 3 years ] [ Designated as safety issue: No ]
    CCE, LV Function, QoL, and Safety will measured.

  • CTA Accuracy [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    The accuracy in the cohort of patients with CTA undergoing ICA (~ n=250) diagnostic test characteristics (sensitivity, specificity, predictive values and likelihood ratios) will be determined and reported with 95% confidence intervals (CI).

  • Resource utilization and cost [ Time Frame: 1, 2, and 3 years ] [ Designated as safety issue: No ]
    Ongoing assessment of resource utilization and cost will be evaluated at 3 additional timepoints covering a 3 year period.

Estimated Enrollment: 250
Study Start Date: February 2011
Estimated Study Completion Date: June 2016
Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Standard imaging (coronary angiography)
Subjects will undergo a coronary angiogram as planned by their attending doctor
Other: Standard Imaging
Other Name: Coronary Angiography
Active Comparator: Advanced imaging (CTA)
Subjects will undergo a CTA scan first. Based on the CTA results, subjects may or may not proceed to coronary angiography. CTA results will be reviewed by the attending physician.
Other: Advanced Imaging
Other Name: Coronary Computed Tomographic Angiography

Detailed Description:

Objectives The primary objective of this randomized control trial (RCT) is to evaluate the clinical utility of an experimental algorithm using CTA and to investigate its potential benefit on resource utilization and health economics in patients with progressive or newly diagnosed heart failure (HF) of unknown etiology (ischemic versus non-ischemic) or in whom the definition of coronary anatomy is required for diagnosis and management. The experimental algorithm will be compared to ICA (Figure 1). The secondary objectives are to compare composite clinical events, quality of life (QoL), major adverse cardiac events (MACE), radiation exposure and safety in both the CTA and ICA arms.

Hypotheses The primary hypothesis is that, compared to ICA, a diagnostic strategy algorithm using CTA for patients with HF (unknown etiology or where the definition of coronary anatomy is required for diagnosis and management) will result in a reduction in downstream resource utilization and per patient cost. The secondary hypotheses are: 1) compared to standard care, a strategy that uses CTA will achieve: a) similar composite clinical events (CCE) (cardiac death, myocardial infarction, resuscitated cardiac arrest and cardiac re-hospitalization (worsening heart failure, acute coronary syndrome arrhythmia), QoL, MACE, b) a lower rate of procedure related complications (death, myocardial infarction, stroke, vascular complications, severe allergic reactions; contrast nephropathy), and c) a lower rate of normal ICA; and 2) using patient-based analysis and vessel-based analysis, CTA has very good agreement with ICA among patients with HF in the CTA arm who proceed to ICA.

Methods/Design Design CTA-HF is a multicentre, multinational, randomized controlled trial that will enrol 250 patients from 15 sites across Canada and Finland over 4 years of recruitment.

Randomization Patients will be randomized to either a CTA or ICA arm and stratified according to recruitment site and pre-test probability. A stratified block (varying sizes) randomization scheme will be used. Within each strata, patients will be randomized with varying block sizes into the two study groups. A central randomization scheme, which will ensure concealment, will be used and the site co-ordinator will perform patient assignments.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Eligibility Criteria All HF patients requiring investigation to determine the etiology of HF (ischemic versus non-ischemic) will be screened for the study.

Inclusion criteria: HF patients with

1a) documented history of left ventricular dysfunction (LVEF <50%).


1b) New York Heart Association (NYHA) Class II-IV symptoms.


1c) an admission to hospital or emergency room for heart failure, in the 12 months prior to enrolment


2) in whom the diagnosis of CAD is uncertain or the definition of coronary anatomy is required for diagnosis and management.

Exclusion criteria:

Patients presenting with any of the following:

  1. age < 18 years or lack of consent,
  2. renal insufficiency (GFR < 45 ml/min)
  3. allergy to intravenous contrast agents
  4. contraindication to radiation exposure (e.g. pregnancy)
  5. uncontrolled heart rate (HR) ( at time of scan (as per local clinical routine)
  6. history of revascularization (CABG or PCI)
  7. atrial fibrillation, frequent atrial or ventricular ectopy (> 1 / minute)
  8. unable to perform 20 second breath-hold;
  9. CTA or ICA within the preceding 12 months.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01283659

Contact: Linda M Garrard, RN, BScN 613-761-4192
Contact: Cathy Kelly, RN 613-761-4809

Canada, Alberta
University of Calgary Recruiting
Calgary, Alberta, Canada
Contact: Todd Anderson, MD         
Principal Investigator: Matthias Friedrich, MD         
University of Alberta Recruiting
Edmonton, Alberta, Canada
Contact: Ian Paterson, MD         
Principal Investigator: Ian Paterson, MD         
Canada, Manitoba
University of Manitoba Not yet recruiting
Winnipeg, Manitoba, Canada
Contact: Malek Kass, MD         
Sub-Investigator: Malek Kass, MD         
Sub-Investigator: James Tan, MD         
Canada, Nova Scotia
Dalhousie University Recruiting
Halifax, Nova Scotia, Canada
Contact: Miroslaw Rajda, MD   
Principal Investigator: Miroslaw Rajda, MD         
Sub-Investigator: James Clarke, MD         
Canada, Ontario
Hamilton Health Sciences Centre Recruiting
Hamilton, Ontario, Canada
Contact: Karen Gulenchyn, MD         
Principal Investigator: Karen Gulenchyn, MD         
London Health Sciences Centre Recruiting
London, Ontario, Canada
Contact: Malcolm Arnold, MD         
Principal Investigator: Malcolm Arnold, MD         
Sub-Investigator: Gerald Wisenberg, MD         
Sub-Investigator: James White, MD         
University of Ottawa Heart Institute Recruiting
Ottawa, Ontario, Canada, K1Y 4W7
Contact: Linda M Garrard, RN, BScN    613-761-4192   
Contact: Cathy Kelly, RN    613-761-4809   
Sub-Investigator: Rob S. Beanlands, MD, FRCP C         
Sub-Investigator: Lisa Mielniczuk, MD, FRCP C         
Sub-Investigator: George A Wells, PhD         
Sub-Investigator: Robert A. deKemp, PhD         
Principal Investigator: Bewnjamin Chow, MD         
St. Michael's Hospital Not yet recruiting
Toronto, Ontario, Canada
Contact: Kim Connelly, MD    14168645201   
Principal Investigator: Kim Connelly, MD         
Sub-Investigator: Michael Freeman, MD         
Sub-Investigator: Howard Leong-Poi, MD         
Sunnybrook Health Sciences Centre Not yet recruiting
Toronto, Ontario, Canada
Contact: Graham Wright, MD    (416)480-6869   
Principal Investigator: Graham Wright, MD         
Principal Investigator: Kim Connelly, MD         
Sub-Investigator: Charles Cunningham Cunningham, MD         
Canada, Quebec
Montreal Heart Institute Recruiting
Montreal, Quebec, Canada
Contact: Eileen O'Meara, MD         
Principal Investigator: Eileen O'Meara, MD         
Sub-Investigator: Jean-Claude Tardif, MD         
University of Laval Recruiting
Quebec City, Quebec, Canada
Contact: Philippe Pibarot, MD         
Principal Investigator: Philippe Pibarot, MD         
Université de Sherbrooke Recruiting
Sherbrooke, Quebec, Canada
Contact: Eric Turcotte, MD         
Principal Investigator: Eric Turcotte, MD         
Sub-Investigator: Serge Lepage, MD         
Sub-Investigator: Paul Pharand, MD         
Helsinki University Central Hospital, Recruiting
Helsinki, Finland
Contact: Mika Laine, MD    358 405 245735   
Principal Investigator: Mika Laine, MD         
University of Kuopio Recruiting
Kuopio, Finland
Contact: Juha Hartikainen, MD    044-711 3945   
Principal Investigator: Juha Hartikainen, MD         
Sub-Investigator: Satu Karkkainen, M D         
University of Turku Recruiting
Turku, Finland
Contact: Juhani Knuuti, MD         
Principal Investigator: Juhani Knuuti, MD         
Sub-Investigator: Heikki Ukkonen, MD         
Sponsors and Collaborators
Ottawa Heart Institute Research Corporation
Canadian Institutes of Health Research (CIHR)
The Finnish Funding Agency for Technology and Innovation (TEKES)
Study Director: Rob SB Beanlands, MD, FRCP C University of OttawaHeart Institute
Principal Investigator: Benjamin Chow, MD, FRCP C Ottawa Heart Institute Research Corporation
  More Information

No publications provided by Ottawa Heart Institute Research Corporation

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Rob Beanlands, Rob S. Beanlands, MD, FRCPC, Chief of Cardiology, University of Ottawa Heart Institute Identifier: NCT01283659     History of Changes
Other Study ID Numbers: Project I-C, CIF-99470
Study First Received: January 20, 2011
Last Updated: August 29, 2014
Health Authority: Canada: Health Canada

Keywords provided by Ottawa Heart Institute Research Corporation:
computed tomographic angiography
coronary angiogram
cost effectiveness
Heart failure
diagnostic accuracy

Additional relevant MeSH terms:
Heart Failure
Cardiovascular Diseases
Heart Diseases processed this record on May 20, 2015